New Math Method Inflates Alzheimer’s Drug Success by 29x

Why It Matters

Inflated efficacy claims can mislead regulators, investors, and clinicians, potentially accelerating approval and reimbursement of drugs with limited real‑world benefit. The findings call for stricter statistical standards in Alzheimer’s research to protect patients and public funds.

Key Takeaways

• Quantile aggregation inflates amyloid‑cognition link by up to 29‑fold.
• Method pools drug and placebo patients, breaking randomization integrity.
• Failed solanezumab trial appeared successful when re‑analyzed with the method.
• Academic audit highlights need for stricter statistical standards in Alzheimer research.

Pulse Analysis

Quantile aggregation has emerged as a seductive tool for summarizing complex trial data, grouping patients into quantiles and averaging outcomes to reveal apparent trends. Proponents argue it simplifies heterogeneous results, but the technique fundamentally assumes homogeneity where none exists, erasing individual variability that can be critical for interpreting therapeutic impact. In the high‑stakes arena of Alzheimer’s therapeutics, where biomarkers like amyloid plaques are heavily scrutinized, such oversimplification can create a misleading narrative of efficacy.

The Brown University team applied the method to both Eli Lilly’s donanemab trial and the long‑failed solanezumab study. Their simulations demonstrated a 29‑times inflation of the amyloid‑cognition relationship, turning a weak or nonexistent signal into a seemingly robust finding. By pooling drug‑receivers with placebo participants, the analysis broke the core principle of randomization, rendering causal inference impossible. The re‑analysis of solanezumab, a drug that showed no cognitive benefit, falsely suggested a strong therapeutic effect, underscoring how the method can resurrect dead‑end candidates.

These revelations have immediate implications for regulators, investors, and clinicians. Overstated efficacy can accelerate FDA approvals, influence Medicare coverage decisions, and inflate market valuations for companies betting on amyloid‑targeting agents. The study urges a return to rigorous, patient‑level analyses and greater transparency in data sharing. As the Alzheimer’s field pivots toward disease‑modifying therapies, adopting robust statistical standards will be essential to ensure that scientific claims translate into genuine clinical value.